{"id":6658,"date":"2020-05-06T15:24:21","date_gmt":"2020-05-06T22:24:21","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=6658"},"modified":"2021-03-16T15:25:08","modified_gmt":"2021-03-16T22:25:08","slug":"tocilizumab-for-the-treatment-of-severe-covid-19","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/05\/06\/tocilizumab-for-the-treatment-of-severe-covid-19\/","title":{"rendered":"Tocilizumab for the Treatment of Severe COVID-19"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Alatt<\/span><span data-contrast=\"auto\">a<\/span><span data-contrast=\"auto\">r et al.\u00a0<\/span><span data-contrast=\"auto\">report a case series\u00a0<\/span><span data-contrast=\"auto\">from 25 patients who had severe COVID-19 and received tocilizumab therapy, an\u00a0<\/span><span data-contrast=\"auto\">i<\/span><span data-contrast=\"auto\">nterleukin-6 inhibitor\u00a0<\/span><span data-contrast=\"auto\">that\u00a0<\/span><span data-contrast=\"auto\">may ameliorate the inflammatory manifestations. During the 14 days of follow-up, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement<\/span><span data-contrast=\"auto\">,<\/span><span data-contrast=\"auto\">\u00a0and reduced ventilator support requirements. However, the majority (92%) of patients experienced at least one adverse event.\u00a0<\/span><span data-contrast=\"auto\">A<\/span><span data-contrast=\"auto\">dequately powered trials<\/span><span data-contrast=\"auto\">\u00a0are needed to confirm efficacy<\/span><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Alattar et al. (May 5, 2020). Tocilizumab for the Treatment of Severe COVID-19<\/span><\/i><span data-contrast=\"auto\">.<\/span><i><span data-contrast=\"none\">\u00a0<\/span><\/i><i><span data-contrast=\"none\">Journal of medical virology<\/span><\/i><i><span data-contrast=\"none\">.<\/span><\/i><i><span data-contrast=\"none\">\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1002\/jmv.25964\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1002\/jmv.25964<\/span><\/a><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alattar et al.\u00a0report a case series\u00a0from 25 patients who had severe COVID-19 and received tocilizumab therapy, an\u00a0interleukin-6 inhibitor\u00a0that\u00a0may ameliorate the inflammatory manifestations. During the 14 days of follow-up, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement,\u00a0and reduced ventilator support requirements. However, the majority (92%) of patients experienced at least one adverse event.\u00a0Adequately&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/05\/06\/tocilizumab-for-the-treatment-of-severe-covid-19\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_members_access_role":[],"_members_access_error":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[19],"class_list":["post-6658","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=6658"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6658\/revisions"}],"predecessor-version":[{"id":6659,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6658\/revisions\/6659"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=6658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=6658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=6658"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=6658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}